DNAH12 inhibitors constitute a distinctive class of chemical compounds meticulously designed to specifically target and modulate the function of the dynein axonemal heavy chain 12 (DNAH12) protein. DNAH12, a pivotal member of the dynein motor protein family, orchestrates the intricate movements of cilia and flagella, specialized organelles essential for a spectrum of cellular activities, including cellular locomotion, sensory perception, and the regulated transport of fluids. These inhibitors are meticulously fashioned to engage with specific binding pockets or catalytic sites on the DNAH12 protein. Upon binding, they intricately disrupt the protein's native motor function, perturbing the complex and precisely orchestrated movement of cilia and flagella. By doing so, DNAH12 inhibitors inherently influence the mechanical properties and dynamic behavior of these microtubule-based structures, directly impacting their capacity to generate the requisite propulsive forces.
The detailed mechanisms that underpin the action of DNAH12 inhibitors involve multifaceted processes. These inhibitors may hinder the ATPase enzymatic activity intrinsic to DNAH12, disrupting the vital energy source that fuels ciliary and flagellar movement. Additionally, DNAH12 inhibitors may impede crucial protein-protein interactions that are indispensable for the proper coordination of DNAH12 within the intricate framework of cilia and flagellar motion. These collective actions culminate in the modulation of ciliary and flagellar dynamics, thus altering their functional outcomes within diverse cellular contexts. The unique nature of DNAH12 inhibitors positions them as indispensable tools for scientific inquiry. Researchers leverage these compounds to meticulously dissect the precise contributions of DNAH12 to the orchestration of ciliary and flagellar activities.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
5-Azacytidine | 320-67-2 | sc-221003 | 500 mg | $280.00 | 4 | |
Azacitidine incorporates into DNA during replication, leading to covalent binding with DNMTs and subsequent DNA hypomethylation, resulting in gene reactivation. | ||||||
5-Aza-2′-Deoxycytidine | 2353-33-5 | sc-202424 sc-202424A sc-202424B | 25 mg 100 mg 250 mg | $218.00 $322.00 $426.00 | 7 | |
Decitabine is converted into its active form, which covalently binds to DNMTs during DNA synthesis, disrupting their activity and causing DNA demethylation. | ||||||
RG 108 | 48208-26-0 | sc-204235 sc-204235A | 10 mg 50 mg | $131.00 $515.00 | 2 | |
RG108 is a small molecule inhibitor that forms a covalent complex with DNMTs, interfering with their catalytic activity and inducing DNA demethylation. | ||||||
Zebularine | 3690-10-6 | sc-203315 sc-203315A sc-203315B | 10 mg 25 mg 100 mg | $129.00 $284.00 $1004.00 | 3 | |
Zebularine is incorporated into DNA and interacts with DNMTs, leading to the inhibition of their activity and promoting DNA demethylation and gene reactivation. | ||||||
SGI-1027 | 1020149-73-8 | sc-473875 | 10 mg | $213.00 | ||
SGI-1027 targets DNMTs by disrupting their binding to DNA, preventing their catalytic activity and inducing DNA hypomethylation, which affects gene expression. | ||||||